Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

Canadian Journal of Cardiology

Volumn 32, Issue 5, 2016, Pages 569-588

  Leung, Alexander A ^a   Nerenberg, Kara ^a   Daskalopoulou, Stella S ^b   McBrien, Kerry ^a   Zarnke, Kelly B ^c   Dasgupta, Kaberi ^b   Cloutier, Lyne ^d   Gelfer, Mark ^e   Lamarre Cliche, Maxime ^f   Milot, Alain ^g   Bolli, Peter ^h   Tremblay, Guy ⁱ   McLean, Donna ^j   Tobe, Sheldon W ^k   Ruzicka, Marcel ^l   Burns, Kevin D ^l   Vallée, Michel ^m   Prasad, G V Ramesh ^k   Lebel, Marcel ^g   Feldman, Ross D ⁿ   Selby, Peter ^k   Pipe, Andrew ^o   Schiffrin, Ernesto L ^p   McFarlane, Philip A ^q   Oh, Paul ^r   Hegele, Robert A ^s   Khara, Milan ^e   Wilson, Thomas W ^t   Penner, S Brian ^u   Burgess, Ellen ^a   Herman, Robert J ^c   Bacon, Simon L ^v   Rabkin, Simon W ^e   Gilbert, Richard E ^q   Campbell, Tavis S ^a   Grover, Steven ^w   Honos, George ^x   Lindsay, Patrice ^y   Hill, Michael D ^z   Coutts, Shelagh B ^z   Gubitz, Gord ^aa   Campbell, Norman R C ^a   Moe, Gordon W ^q   Howlett, Jonathan G ^c   Boulanger, Jean Martin ^ab   Prebtani, Ally ^ac   Larochelle, Pierre ^f   Leiter, Lawrence A ^ad   Jones, Charlotte ^e   Ogilvie, Richard I ^r   Woo, Vincent ^u   Kaczorowski, Janusz ^x   Trudeau, Luc ^ae   Petrella, Robert J ^s   Hiremath, Swapnil ^l   Drouin, Denis ^g   Lavoie, Kim L ^af   Hamet, Pavel ^x   Fodor, George ^o   Grégoire, Jean C ^ag   Lewanczuk, Richard ^j   Dresser, George K ^ah   Sharma, Mukul ^ai   Reid, Debra ^aj   Lear, Scott A ^ak   Moullec, Gregory ^al   Gupta, Milan ^k,ac   Magee, Laura A ^am   Logan, Alexander G ^k   Harris, Kevin C ^e   Dionne, Janis ^e   Fournier, Anne ^an   Benoit, Geneviève ^an   Feber, Janusz ^ao   Poirier, Luc ⁱ   Padwal, Raj S ^j   Rabi, Doreen M ^c   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^g UNIVERSITÉ LAVAL   (Canada)

^h Ambulatory Internal Medicine Teaching Clinic   (Canada)

ⁱ LAVAL UNIVERSITY   (Canada)

^j UNIVERSITY OF ALBERTA   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^m MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁿ MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^o UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^p MCGILL UNIVERSITY   (Canada)

^q ST MICHAEL'S HOSPITAL   (Canada)

^r UNIVERSITY HEALTH NETWORK   (Canada)

^s UNIVERSITY OF WESTERN ONTARIO   (Canada)

^t UNIVERSITY OF SASKATCHEWAN   (Canada)

^u UNIVERSITY OF MANITOBA   (Canada)

^v Hôpital du Sacré Coeur de Montréal   (Canada)

^w MONTREAL GENERAL HOSPITAL   (Canada)

^x UNIVERSITÉ DE MONTRÉAL   (Canada)

^y HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^z UNIVERSITY OF CALGARY   (Canada)

^aa DALHOUSIE UNIVERSITY   (Canada)

^ab UNIVERSITÉ DE SHERBROOKE   (Canada)

^ac MCMASTER UNIVERSITY   (Canada)

^ad ST MICHAEL'S HOSPITAL   (Canada)

^ae MCGILL UNIVERSITY   (Canada)

^af UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^ag MONTREAL HEART INSTITUTE   (Canada)

^ah WESTERN UNIVERSITY   (Canada)

^ai Canadian Stroke Network   (Canada)

^aj DEPARTMENT OF NATIONAL DEFENCE   (Canada)

^ak SIMON FRASER UNIVERSITY   (Canada)

^al HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^am ST GEORGE S HOSPITAL   (United Kingdom)

^an UNIVERSITY OF MONTREAL   (Canada)

^ao CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; MINOXIDIL; NIFEDIPINE; POTASSIUM; RENIN INHIBITOR; SODIUM; SULFAMETHOXAZOLE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG;

ADRENALECTOMY; ALCOHOL CONSUMPTION; ALDOSTERONE RELEASE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BEHAVIOR MODIFICATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CALCIUM INTAKE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLASSIFICATION ALGORITHM; CLINICAL PROTOCOL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC HYPERTENSION; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; EDUCATION PROGRAM; ELECTRIC POTENTIAL; EVIDENCE BASED PRACTICE; EXERCISE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; LABORATORY TEST; LUNG EDEMA; MAGNESIUM INTAKE; MEDLINE; MICROALBUMINURIA; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHEOCHROMOCYTOMA; POTASSIUM INTAKE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIMARY HYPERALDOSTERONISM; PROTEINURIA; RELAXATION TRAINING; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION; SMOKING CESSATION; SODIUM INTAKE; STABLE ANGINA PECTORIS; STRESS MANAGEMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; WEIGHT REDUCTION; WHITE COAT HYPERTENSION; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CANADA; EVIDENCE-BASED MEDICINE; HEALTH EDUCATION; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS;

EID: 84964334324     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.02.066     Document Type: Article

References (85)

1. Padwal R.S., Bienek A., McAlister F.A., Campbell N.R.C. Outcomes Research Task Force of the Canadian Hypertension Education Program. Epidemiology of hypertension in Canada: an update. Can J Cardiol 2016, 32:687-694.
2. Kannel W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996, 275:1571-1576.
3. Yusuf S., Hawkins S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
4. Lim S.S., Vos T., Flaxman A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
5. Chow C.K., Teo K.K., Rangarajan S., et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013, 310:959-968.
6. McAlister F.A., Wilkins K., Joffres M., et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011, 183:1007-1013.
7. Feldman R.D., Campbell N., Larochelle P., et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. CMAJ 1999, 161(suppl 12):S1-S17.
8. Zarnke K.B., Levine M., McAlister F.A., et al. The 2000 Canadian recommendations for the management of hypertension: part two-diagnosis and assessment of people with high blood pressure. Can J Cardiol 2001, 17:1249-1263.
9. Zarnke K.B., McAlister F.A., Campbell N.R., et al. The 2001 Canadian recommendations for the management of hypertension: part one-assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Can J Cardiol 2002, 18:604-624.
10. McAlister F.A., Zarnke K.B., Campbell N.R., et al. The 2001 Canadian recommendations for the management of hypertension: part two-therapy. Can J Cardiol 2002, 18:625-641.
11. Canadian Hypertension Education Program The Canadian recommendations for the management of hypertension. Can Pharm J 2003, 136:45-52.
12. Hemmelgarn B.R., Zarnke K.B., Campbell N.R., et al. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: part I-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2004, 20:31-40.
13. Khan N.A., McAlister F.A., Campbell N.R., et al. The 2004 Canadian recommendations for the management of hypertension: part II-therapy. Can J Cardiol 2004, 20:41-54.
14. Touyz R.M., Campbell N., Logan A., et al. The 2004 Canadian recommendations for the management of hypertension: part III-lifestyle modifications to prevent and control hypertension. Can J Cardiol 2004, 20:55-59.
15. Hemmelgarn B.R., McAllister F.A., Myers M.G., et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2005, 21:645-656.
16. Khan N.A., McAlister F.A., Lewanczuk R.Z., et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II-therapy. Can J Cardiol 2005, 21:657-672.
17. Hemmelgarn B.R., McAlister F.A., Grover S., et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part I-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2006, 22:573-581.
18. Khan N.A., McAlister F.A., Rabkin S.W., et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II-therapy. Can J Cardiol 2006, 22:583-593.
19. Padwal R.S., Hemmelgarn B.R., McAlister F.A., et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2007, 23:529-538.
20. Khan N.A., Hemmelgarn B., Padwal R., et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2007, 23:539-550.
21. Padwal R.S., Hemmelgarn B.R., Khan N.A., et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2008, 24:455-463.
22. Khan N.A., Hemmelgarn B., Herman R.J., et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2008, 24:465-475.
23. Padwal R.S., Hemmelgarn B.R., Khan N.A., et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2009, 25:279-286.
24. Khan N.A., Hemmelgarn B., Herman R.J., et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2009, 25:287-298.
25. Quinn R.R., Hemmelgarn B.R., Padwal R.S., et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2010, 26:241-248.
26. Hackam D.G., Khan N.A., Hemmelgarn B.R., et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2010, 26:249-258.
27. Rabi D.M., Daskalopoulou S.S., Padwal R.S., et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011, 27:415-433.
28. Daskalopoulou S.S., Khan N.A., Quinn R.R., et al. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2012, 28:270-287.
29. Hackam D.G., Quinn R.R., Ravani P., et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013, 29:528-542.
30. Dasgupta K., Quinn R.R., Zarnke K.B., et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014, 30:485-501.
31. Daskalopoulou S.S., Rabi D.M., Zarnke K.B., et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2015, 31:549-568.
32. Harris K.C., Benoit G., Dionne J., et al. Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, and assessment of risk of pediatric hypertension. Can J Cardiol 2016, 32:589-597. for the CHEP Guidelines Task Force.
33. McAlister F.A. The Canadian Hypertension Education Program-a unique Canadian initiative. Can J Cardiol 2006, 22:559-564.
34. Wright J.T., Williamson J.D., Whelton P.K., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015, 373:2103-2116.
35. Brouwers M.C., Kho M.E., Browman G.P., et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010, 182:E839-E842.
36. Myers M.G. A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement. J Hypertens 2010, 28:703-708.
37. Myers M.G. The great myth of office blood pressure measurement. J Hypertens 2012, 30:1894-1898.
38. Myers M.G. Eliminating the human factor in office blood pressure measurement. J Clin Hypertens (Greenwich) 2014, 16:541-542.
39. Myers M.G., Godwin M. Automated measurement of blood pressure in routine clinical practice. J Clin Hypertens (Greenwich) 2007, 9:267-270.
40. Myers M.G., Godwin M., Dawes M., et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011, 342:d286.
41. Myers M.G., Godwin M., Dawes M., et al. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Fam Pract 2012, 29:376-382.
42. Myers M.G., Valdivieso M., Kiss A. Consistent relationship between automated office blood pressure recorded in different settings. Blood Press Monit 2009, 14:108-111.
43. Myers M.G., Valdivieso M., Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens 2009, 27:280-286.
44. Myers M.G., Godwin M., Dawes M., et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 2010, 55:195-200.
45. Myers M.G., Oh P.I., Reeves R.A., Joyner C.D. Prevalence of white coat effect in treated hypertensive patients in the community. Am J Hypertens 1995, 8:591-597.
46. Armstrong D., Matangi M., Brouillard D., Myers M.G. Automated office blood pressure - being alone and not location is what matters most. Blood Press Monit 2015, 20:204-208.
47. Greiver M., White D., Kaplan D.M., et al. Where should automated blood pressure measurements be taken? Pilot RCT of BpTRU measurements taken in private or nonprivate areas of a primary care office. Blood Press Monit 2012, 17:137-138.
48. Chambers L.W., Kaczorowski J., O'Rielly S., Ignagni S., Hearps S.J. Comparison of blood pressure measurements using an automated blood pressure device in community pharmacies and family physicians' offices: a randomized controlled trial. CMAJ Open 2013, 1:E37-E42.
49. Andreadis E.A., Agaliotis G.D., Angelopoulos E.T., et al. Automated office blood pressure and 24-h ambulatory measurements are equally associated with left ventricular mass index. Am J Hypertens 2011, 24:661-666.
50. Andreadis E.A., Agaliotis G.D., Angelopoulos E.T., et al. Automated office blood pressure is associated with urine albumin excretion in hypertensive subjects. Am J Hypertens 2012, 25:969-973.
51. Campbell N.R., McKay D.W., Conradson H., et al. Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima-medial thickness in male firefighters. J Hum Hypertens 2007, 21:588-590.
52. Myers M.G., Kaczorowski J., Paterson J.M., Dolovich L., Tu K. Thresholds for diagnosing hypertension based on automated office blood pressure measurements and cardiovascular risk. Hypertension 2015, 66:489-495.
53. Sidhu D., Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med 2012, 172:1707-1710.
54. Doran B., Guo Y., Xu J., et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 2014, 130:546-553.
55. Langsted A., Freiberg J.J., Nordestgaard B.G. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008, 118:2047-2056.
56. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853. [erratum in 1999;354:602].
57. Bansal S., Buring J.E., Rifai N., et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
58. Di Angelantonio E., Sarwar N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
59. Nordestgaard B.G., Varbo A. Triglycerides and cardiovascular disease. Lancet 2014, 384:626-635.
60. Aldasouqi S., Sheikh A., Klosterman P., et al. Hypoglycemia in patients with diabetes on antidiabetic medications who fast for laboratory tests. Diabetes Care 2011, 34:e52.
61. de Vries M., Klop B., Castro Cabezas M. The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - point of view. Atherosclerosis 2014, 234:473-475.
62. Khera A.V., Mora S. Fasting for lipid testing: is it worth the trouble?. Arch Intern Med 2012, 172:1710-1712.
63. Doppman J.L., Gill J.R., Miller D.L., et al. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: reliability of CT. Radiology 1992, 184:677-682.
64. Harper R., Ferrett C.G., McKnight J.A., et al. Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas. QJM 1999, 92:643-650.
65. Magill S.B., Raff H., Shaker J.L., et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001, 86:1066-1071.
66. McAlister F.A., Lewanczuk R.Z. Primary hyperaldosteronism and adrenal incidentaloma: an argument for physiologic testing before adrenalectomy. Can J Surg 1998, 41:299-305.
67. Nwariaku F.E., Miller B.S., Auchus R., et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006, 141:497-502. [discussion: 502-493].
68. Young W.F., Stanson A.W., Thompson G.B., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004, 136:1227-1235.
69. Kempers M.J., Lenders J.W., van Outheusden L., et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009, 151:329-337.
70. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005, 25(suppl 1):S143-S158.
71. Vonend O., Ockenfels N., Gao X., et al. Adrenal venous sampling: evaluation of the German Conn's registry. Hypertension 2011, 57:990-995.
72. Kline G.A., Pasieka J.L., Harvey A., So B., Dias V.C. High-probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false-positive diagnoses. J Clin Hypertens (Greenwich) 2014, 16:488-496.
73. Harvey A., Pasieka J.L., Kline G., So B. Modification of the protocol for selective adrenal venous sampling results in both a significant increase in the accuracy and necessity of the procedure in the management of patients with primary hyperaldosteronism. Surgery 2012, 152:643-649. [discussion: 649-51].
74. Sacks F., Svetkey L., Vollmer W., et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001, 344:3-10.
75. Moore T.J., Vollmer W.M., Appel L.J., et al. Effect of dietary patterns on ambulatory blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. Hypertension 1999, 34:472-477.
76. Karanja N.M., Obarzanek E., Lin P.H., et al. Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. J Am Diet Assoc 1999, 99:S19-S27.
77. Appel L., Moore T., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997, 336:1117-1124.
78. Aburto N.J., Hanson S., Gutierrez H., et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013, 346:f1378.
79. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
80. Ettehad D., Emdin C.A., Kiran J., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016, 387:957-967.
81. Xie X., Atkins E., Lv J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016, 387:435-443.
82. Mancini G.B., Gosselin G., Chow B., et al. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol 2014, 30:837-849.
83. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2816.
84. Dargie H.J., Ford I., Fox K.M. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996, 17:104-112.
85. Rehnqvist N., Hjemdahl P., Billing E., et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996, 17:76-81.